Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform

Rhea-AI Filing Summary

Polyrizon Ltd., a development-stage biotech company focused on intranasal hydrogels, reported that a U.S. patent application covering its Trap & Target™ mucoadhesive nasal drug delivery platform has been published as patent application No. US 2024/0358741 A1.

The application describes biocompatible mucoadhesive polymers that form a durable film on mucosal surfaces to enhance retention, absorption, and sprayability for nasal and oral formulations. Potential uses include sprays, gels, inhalation products, and localized or systemic delivery of drugs such as anti-inflammatories, vaccines, biologics, and other active ingredients.

Polyrizon positions this Trap & Target technology alongside its existing Capture and Contain™ hydrogel “biological mask” platform, both aimed at improving nasal barrier protection and drug delivery. The company cautions that there is no assurance any patent will ultimately issue from the pending application.

Key Figures

Patent application number: US 2024/0358741 A1 Form type: Form 6-K Annual report form: Form 20-F +4 more

7 metrics

Patent application number US 2024/0358741 A1 U.S. patent application for mucoadhesive nasal drug delivery

Form type Form 6-K Report of Foreign Private Issuer for June 2026

Annual report form Form 20-F Referenced for the fiscal year ended December 31, 2025

S-8 registration file numbers 333-284410 and 333-288923 Incorporation by reference of portions of the press release

F-3 registration file number 333-291368 Incorporation by reference of portions of the press release

Press release date June 17, 2026 Date of patent publication announcement

Fiscal year end December 31, 2025 Referenced in risk discussion for Annual Report on Form 20-F

Key Terms

mucoadhesive polymer technology, biocompatible mucoadhesive compositions, Capture and Contain TM, development stage biotech company, +2 more

6 terms

mucoadhesive polymer technology medical

"covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery"

biocompatible mucoadhesive compositions medical

"describes biocompatible mucoadhesive compositions designed to form a uniform and durable film on mucosal surfaces"

Capture and Contain TM medical

"Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks"

development stage biotech company financial

"Polyrizon Ltd. ... a development-stage biotech company specializing in the development of innovative intranasal hydrogels"

forward-looking statements regulatory

"This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

mucosal retention and bioavailability medical

"with the goal of improving mucosal retention and bioavailability"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of June 2026

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

8 Ha-Pnina Street

Raanana, 4321545, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on June 17, 2026, titled “Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform.”

The first five paragraphs of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923) and Form F-3 (333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: June 17, 2026	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

3

Exhibit 99.1

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform

Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the publication of U.S. patent application No. US 2024/0358741 A1, titled “Mucoadhesive Polymers for Nasal Drug Delivery”.

The patent application covers Polyrizon’s proprietary Trap & Target™ (T&T) mucoadhesive polymer technology platform for nasal drug delivery. The technology is designed to enhance the interaction between pharmaceutical formulations and the nasal mucosa, potentially increasing formulation retention, improving drug absorption, and enabling more efficient delivery of active pharmaceutical ingredients through the nasal route.

The published patent application describes biocompatible mucoadhesive compositions designed to form a uniform and durable film on mucosal surfaces while enabling enhanced delivery and retention of pharmaceutical actives. The technology combines sulfated polysaccharides, with hydrophilic polymers, partially crosslinked with divalent ions to create formulations with improved viscosity, sprayability, and film-forming properties.

The patent application further outlines the potential use of the platform in oral and nasal drug delivery systems, including sprays, gels, inhalation products, and formulations intended for localized and systemic administration of therapeutic agents through mucosal tissues.

According to the application, the platform may support delivery of a broad range of therapeutic compounds, including anti-inflammatory drugs, vaccines, biologics, and additional pharmaceutical actives, with the goal of improving mucosal retention and bioavailability.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain ^TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential uses and benefits of its technology. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

What did Polyrizon (PLRZ) announce in its latest Form 6-K?

Polyrizon announced publication of U.S. patent application US 2024/0358741 A1 covering its Trap & Target mucoadhesive nasal drug delivery platform. The filing highlights polymer compositions designed for improved mucosal retention, absorption, and sprayability for nasal and oral pharmaceutical formulations.

What is Polyrizon’s Trap & Target (T&T) mucoadhesive platform?

Trap & Target is Polyrizon’s proprietary mucoadhesive polymer technology for nasal drug delivery. It aims to form a uniform, durable film on mucosal surfaces, improving retention and absorption of active pharmaceutical ingredients in sprays, gels, inhalation products, and other mucosal drug delivery systems.

Which therapies could Polyrizon’s new platform potentially deliver?

According to the application, Polyrizon’s platform may support delivery of anti-inflammatory drugs, vaccines, biologics, and other active pharmaceutical ingredients. It is intended for nasal and oral formulations, including sprays and gels, to enhance mucosal retention and bioavailability of therapeutic compounds.

How does Trap & Target differ from Polyrizon’s Capture and Contain technology?

Capture and Contain is a hydrogel nasal spray platform that forms a barrier or “biological mask” against viruses and allergens. Trap & Target focuses on mucoadhesive polymers for intranasal drug delivery, aiming to improve retention and absorption of active pharmaceutical ingredients at mucosal sites.

Does the patent publication guarantee Polyrizon will receive a U.S. patent?

No, Polyrizon explicitly states it cannot assure that any patent will issue from the pending application. Even if a patent is granted, the company notes it may not issue in a form that is advantageous, and outcomes could differ from current expectations.

What stage of development is Polyrizon’s Trap & Target technology in?

Polyrizon describes Trap & Target as being in an earlier stage of pre-clinical development. It is part of the company’s broader effort to use hydrogel and mucoadhesive technologies to support nasal delivery of active pharmaceutical ingredients and improve mucosal drug delivery performance.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE TITLED: "POLYRIZON RECEIVES NOTICE OF U.S. PATENT PUBLICATION FOR 7.9 KB